Irritable Bowel Syndrome Characterized by Constipation

Gastroenterology
7
Pipeline Programs
2
Companies
6
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
4
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
5100%
+ 1 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
LINACLOTIDEApproved
linaclotide
Unknown Company
oral2023

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Ironwood Pharmaceuticals
3 programs
2
1
LinaclotidePhase 4Peptide1 trial
LinaclotidePhase 3Peptide1 trial
Linaclotide 290 microgramsPhase 31 trial
Active Trials
NCT03573908CompletedEst. Apr 2019
NCT00948818CompletedEst. Aug 2010
NCT02837783TerminatedEst. Oct 2018
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
3 programs
1
2
PlecanatidePhase 3Peptide1 trial
PlecanatidePhase 3Peptide1 trial
PlecanatidePhase 2Peptide1 trial
Active Trials
NCT01722318CompletedEst. Oct 2014
NCT02493452CompletedEst. Feb 2017
NCT02387359CompletedEst. Feb 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ironwood PharmaceuticalsLinaclotide
Ironwood PharmaceuticalsLinaclotide
Bausch HealthPlecanatide
Bausch HealthPlecanatide
Ironwood PharmaceuticalsLinaclotide 290 micrograms
Bausch HealthPlecanatide

Clinical Trials (6)

NCT02837783Ironwood PharmaceuticalsLinaclotide

A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)

Start: Dec 2016Est. completion: Oct 2018
Phase 4Terminated
NCT03573908Ironwood PharmaceuticalsLinaclotide

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Start: Jun 2018Est. completion: Apr 2019
Phase 3Completed
NCT02493452Bausch HealthPlecanatide

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

Start: Jun 2015Est. completion: Feb 2017
Phase 3Completed
NCT02387359Bausch HealthPlecanatide

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Start: Dec 2014Est. completion: Feb 2017
Phase 3Completed
NCT00948818Ironwood PharmaceuticalsLinaclotide 290 micrograms

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

Start: Jul 2009Est. completion: Aug 2010
Phase 3Completed
NCT01722318Bausch HealthPlecanatide

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Start: Nov 2012Est. completion: Oct 2014
Phase 2Completed

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
7h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
Peptide is the dominant modality (100% of programs)
2 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)